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We present the synthesis, structure determination, and thermodynamic properties of a never reported cocrystal
prepared with lidocaine and L-menthol. The temperature-composition phase diagram of the lidocaine/L-menthol
binary system was achieved using differential scanning calorimetry and X-ray diffraction experiments. The present
study demonstrates that the only way to perform a phase equilibrium survey of the lidocaine/L-menthol system is
to prepare the binary mixtures from the cocrystal, an equimolar stoichiometric compound of L-menthol and lidocaine.
We describe a process that is crucial to elaborate pharmaceutical agents that remain in their thermodynamical
stable state throughout their preparation, manufacture, and storage for effective use.
Introduction
2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide, other-
wise known as lidocaine, is classified as an amide type anesthetic
compound. This drug is usually used for local transdermal
application before venipuncture1 or minor surgical procedures.2
Eutectic mixtures based on lidocaine/excipient association are
often prepared for this purpose.3-5 The choice of the excipient
is crucial to ensure its thermodynamic stability, nontoxicity, and
bioavailability. For proper therapeutic use, the eutectic mixture
has to remain in the liquid state in a temperature range below
room temperature. That is the reason why the active pharma-
ceutical ingredient (API) and the excipient interactions must
be studied in their thermodynamic stable phase. Moreover, the
excipient, which can be helpful for a better delivery of the drug
through the skin, has to be harmless. EMLA eutectic mixture
(AstraZeneca PLC, London, U.K.), with lidocaine and prilocaine
as therapeutic agents, has been developed and is widely used,
especially in medical care for children. Nevertheless, prilocaine,
known as a methemoglobin inducer, displays pathologic issues
during the drug metabolism.6,7 L-Menthol, a transdermal en-
hancer agent for API,8 is often considered as a suitable excipient
for the eutectic preparations using topical anesthesia.9 The
lidocaine/L-menthol binary mixture has been recently patented10
and the corresponding temperature-composition (T-x) phase
diagram published by Kang and co-workers.11 At first sight, the
diagram could indicate a liquid/liquid demixtion around the
equimolar binary composition. However, upon further investiga-
tion, we discovered that the phase diagram exhibits inconsisten-
cies with respect to the invariant equilibrium. The latter manifest
themselves at ∼39 °C and for lidocaine molar ratios around
the equimolar composition. We hypothesized that the existence
of a stoichiometric compound (cocrystal)12-15 at x ) 0.5 could
explain the formation of the invariant equilibrium. A schematic
representation of a common building blocksa three-membered
assembly (lidocaine)2 · (L-menthol)swithin the cocrystal is
proposed in Scheme 1. Deeper investigations of the phase
diagram were thus carried out in order to check this conjecture.
Subsequently, single crystals of a 1:1 stoichiometric compound
were obtained. This new compound was characterized by single
crystal X-ray diffraction and thermal analysis. Taking into
account this compound, the stable T-x phase diagram was
established. The metastable phase diagrams were established
as well and compared from a thermodynamic point of view with
the stable one.
Experimental Section
Materials. Lidocaine (purity g98.5%; CAS 137-58-6) and
L-menthol (purity: 99.7%; CAS 2216-51-5) were purchased from
Sigma-Aldrich and Acros Organics, respectively. No further
purification steps were necessary.
Cocrystal Synthesis. The stoichiometric compound was
obtained by melting a mixture of lidocaine and L-menthol in
equimolar proportion at 90 °C in a glass vial. Then, the vial
was quenched first at -80 °C for 10 min to obtain a glassy
phase, and finally heated from -80 °C to room temperature.
Spontaneously, crystals of the 1:1 compound (Figure 1) were
formed by nucleation during warming of the sample. The vial
was sealed in order to avoid L-menthol evaporation during the
heating and cooling processes.
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SCHEME 1: Structure of the Molecular Assembly
Proposed to Form in the Lidocaine:L-Menthol Cocrystala
a Hydrogen bonds are represented by dashed lines.
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Sample Preparations for the DSC Runs. The stable T-x
phase diagram of lidocaine/L-menthol was established by
mechanically mixing in a mortar the stoichiometric compound
with lidocaine, or L-menthol, all in their solid state. The 1:1-
compound/L-menthol mixtures were prepared in a 3 °C cold
room, whereas the 1:1-compound/lidocaine ones were prepared
at room temperature. For an optimum equilibrium profile, the
lidocaine-rich sealed samples were stored in an oven at 35 °C
after the preparation. After 1 month, the differential scanning
calorimetry (DSC) experiments were performed.
The metastable phase diagrams with invariant points at 0.3
and 12.3 °C were obtained after recrystallization of the molten
mixtures by cycling three times from -60 to -2 °C at a 10
K ·min-1 scan rate and by annealing at -5 °C for 1 month,
respectively.
Single-Crystal X-ray Diffraction. A crystal (120 μm × 100
μm × 60 μm) was trapped by a gripper and placed in a nitrogen
environment at 234 K. A capillary was inserted between the
gripper and the N2 flow in order to protect the crystal. Data
were collected with an R-Axis Rapid Rigaku MSC diffracto-
meter using the Cu KR radiation and a graphite monochromator.
All reflections were used for unit cell refinement. The Mercury
2.2 program was used for analysis and graphic representation.16
Other programs such as Materials Studio Modeling 4.117 and
ORTEP-3 2.0218 were also used for drawing the molecular
graphics. The crystal structure was solved by direct methods
Shelx 8619 and refined using the Shelx 9720 suite of programs.
The positions of the H atoms were deduced from coordinates
of the non-H atoms and confirmed by Fourier synthesis. The
non-H atoms were refined with anisotropic temperature param-
eters. Nonrefined H atoms were included for structure factor
calculations.
Thermal Analysis. Temperatures and enthalpies of fusion
were determined using a differential scanning calorimeter
(Mettler-Toledo, Switzerland) calibrated beforehand with high
purity indium and zinc reference samples. DSC runs were
performed at 5 K ·min-1 under an atmosphere of dry nitrogen
gas. For more accurate statistics, the experiments on pure
compounds (lidocaine, L-menthol) and on the 1:1 compound
were reproduced at different scan rates and with different sample
weights. No variation of the enthalpy of fusion vs the specific
volume of the sample, namely, V/m,21 was observed with these
three components.
Results and Discussion
1. Characterization of the Cocrystal. The crystal structure
of the 1:1 stoichiometric compound was established by single
X-ray diffraction (Cambridge Crystallographic Data Centre
reference number 753770), and the collected data are presented
in Table 1. The lidocaine:L-menthol addition compound crystal-
lizes in a P212121 orthorhombic space group (Figure 2). The
conformation of the corresponding molecules within the crystal
is shown in Figure 3. As a reminder, the crystal structures of
stable L-menthol22 (named the R-phase) and lidocaine23 have
Figure 1. Micrograph of the lidocaine:L-menthol cocrystals immersed
in an enriched L-menthol liquid phase.
TABLE 1: Crystal Data and Structure Refinement
Parameters for the Lidocaine:L-Menthol 1:1 Compound
formula C24H42N2O2
FW (g ·mol-1) 390.60
temperature 233 K
wavelength 1.54180 Å
cryst. syst. orthorhombic
space group P212121
unit cell dimensions
a (Å) 8.4016(5)
b (Å) 13.4207(9)
c (Å) 22.130(2)
volume (Å3) 2495.3(4)
Z 4
Dx (g · cm-3) 1.040
μ (mm-1) 0.503
R1, I > 2σ(I) 0.0485
wR2, I > 2σ(I) 0.1151
S 1.011
Figure 2. (A) Crystal structure of the lidocaine:L-menthol compound.
(B) Geometry of the hydrogen bonds within the cocrystal. Hydrogen
bonds are represented by dashed lines. Intra- and intermolecular
hydrogen bonds are colored in cyan and green, respectively.
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already been published. The corresponding space groups are
P31 trigonal and P21/C monoclinic, respectively. The CIF
documents resulting from the X-ray experiments performed on
cocrystal and on pure lidocaine and L-menthol were examined
regarding bond lengths, angles, and torsion angles (see the
Supporting Information). The conformational organization of
the lidocaine and L-menthol molecules within the cocrystal may
be said to be not significantly different compared to their
organization within the lidocaine or L-menthol crystals. The pure
lidocaine crystal is made up of a dimeric asymmetric unit, but
within the cocrystal, the lidocaine asymmetric unit becomes
monomeric. As far as the L-menthol crystal is concerned, its
trimeric motif turns into a monomeric motif in the cocrystal.
As indicated in Figure 2B and compared to the pure lidocaine
structure,23 the intramolecular hydrogen bonds resulting from the
trans-amide configuration (chelate form) of the lidocaine are
conserved in the cocrystal structure, with a slight increase of the
N-H · · ·N hydrogen-bond length and angle: 2.24 to 2.31 Å and
110.0 to 112.3°, respectively (Table 2). The related decrease of
the intramolecular hydrogen-bond interactions in the cocrystal is
balanced by the presence of two intermolecular hydrogen-bond
types. Indeed, the O-H · · ·O one-cohesion interaction between two
alcohol residues in the L-menthol networkswhich accounts for the
stability of the crystalline edificesis replaced in cocrystal by the
O-H · · ·O and N-H · · ·O types between L-menthol and lidocaine
residues. These hydrogen bonds have longer lengths and
smaller angles compared to the former intermolecular
O-H · · ·O hydrogen bond in pure L-menthol.22
The thermodynamic data of the 1:1 compound were deter-
mined from DSC results. A congruent melting behavior was
identified with a melting point at 39.1 ( 0.2 °C and an enthalpy
of fusion of 98.0 ( 0.8 J ·g-1 (i.e., 38.3 kJ/mol of cocrystal or
19.2 kJ/mol of lidocaine). To sum up, the lidocaine, L-menthol,
and 1:1 compound experimental thermodynamic data are
gathered in Table 3.
2. Lidocaine/L-Menthol Stable Phase Diagram. DSC ex-
periments performed with the mixed solids (stoichiometric
compound with L-menthol or lidocaine) lead to signals of the
heat flow vs temperature as presented in Figure 4. The results
exhibit two distinguishable tendencies between thermograms
obtained for lidocaine molar ratio before and after the equimolar
composition (Figure 4), leading to the phase diagram depicted
in Figure 5. In this figure, the ideal liquidus calculated using
the Schro¨der-van Laar relation24-26 (eq 1) has also been
reported for comparison. One can observe a small deviation of
the experimental phase diagram from the ideal one especially
in the lidocaine-rich part of the diagram.
ΔfusH
R · ( 1Tfus - 1Tx) ) ln(X) (1)
with X ) x for the liquidus obtained from L-menthol and from
lidocaine. X ) 4x · (1 - x) for the two liquidi obtained from the
equimolar compound.27 x stands for the molar ratio of one of the
pure components, and Tx, the liquidus temperature of the corre-
sponding mixture. ΔfusH and Tfus are, respectively, the enthalpy
and the temperature of fusion of either the pure compounds
Figure 3. Oak Ridge thermal ellipsoid plot (ORTEP, 50% probability) of lidocaine (A) and L-menthol (B) within the cocrystal.
TABLE 2: Hydrogen Bond Geometry in the Cocrystala
length (Å) angle (deg)
H-bond type D-H · · ·A D-H H · · ·A D · · ·A D-H · · ·A
intermolecular N-H · · ·O 0.870 2.213 3.029 155.96
O-H · · ·O 0.830 2.084 2.818 147.12
intramolecular N-H · · ·N 0.869 2.309 2.731 109.94
a D and A stand for H-donor and H-acceptor, respectively. Bold
elements belong to L-menthol.
TABLE 3: Experimental Temperatures and Enthalpies of
Fusion for the Pure Components and the Cocrystal
Tfus (°C) ΔfusH (kJ ·mol-1)
1:1 compound 39.1 ( 0.2 38.3 ( 0.3
L-menthol 42.9 ( 0.3 14.1 ( 0.2
lidocaine 68.6 ( 0.5 16.9 ( 0.2
Figure 4. Weight-normalized DSC thermograms of lidocaine/L-menthol
mixtures. Lidocaine molar ratios: 0.00, 0.05, 0.20, 0.45, 0.50, 0.54,
0.75, 0.95, and 1.00 from the bottom to the top curves, respectively.
The thermograms were shifted for clarity. The dotted lines correspond
to the thermograms of the pure compounds and the 1:1 compound.
Endothermic transformations give signals pointing up.
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or the cocrystal. R is the gas constant. The temperatures are
in kelvin.
The T-x phase diagram confirms that the stoichiometric
compound presents a congruent melting. On either side of the
equimolar composition, two eutectic invariants are formed with
lidocaine and L-menthol. X-ray powder diffraction experiments
have shown that no solid solution is formed for enriched lidocaine
or L-menthol solid mixtures (see the Supporting Information).
The Tammann plots (Figure 6) allowed determining the
temperature and composition of the eutectic points: xe,1, 0.20;
Te,1, 28.6 °C; xe,2, 0.61; Te,2, 37.6 °C. These plots also confirm
that no miscibility is encountered between cocrystal and
L-menthol or lidocaine, since the straight lines intercept ΔHe )
0 at x ) 0, x ) 0.5, and x ) 1.
The 1:1 compound exhibits a complete dissociation in the
liquid state and follows the ideal associated solution model.28
Indeed, the region of the T-x diagram between the two eutectic
points obeys eq 2.27
where x corresponds to the molar ratio of a constituent, ΔfusH
the enthalpy of fusion, T the temperature in kelvin, and R
the gas constant. i and j are the stoichiometric coefficients
of the i:j compound. The subscript C refers to the quantities
at the congruent melting point with TC ) 39.1 °C (from the
DSC experiments).
Besides, the plot ln[x(x - 1)] vs (1/T - 1/TC) is a straight
line (Figure 7). It comes from the ((1/T - 1/TC) ) 0)-intercept
that ln[(xC)i(1 - xC)j] is equal to -1.39, which gives a value of
0.50 for xC. This result confirms the formation of the 1:1
lidocaine:L-menthol compound. The slope of the straight line
(-ΔfusH/R) is equal to -4.63 × 103 ( 0.03 × 103 K. This leads
to an enthalpy of fusion of the 1:1 compound equal to 38.5
kJ ·mol-1, with an error of 1.1 kJ ·mol-1 estimated from the
linear regression, in agreement with the experimental result
(Table 3).
It is noteworthy that, when direct contact between lidocaine
and L-menthol or between L-menthol and the 1:1 compound
occurs at room temperature, molten mixtures are observed. The
thus-obtained liquids do not systematically recrystallize, even
by the thaw-melt method.29 These remarks are in accordance
with Kang et al.’s observations concerning the two-year stability
of the homogeneous oil phase at 25 °C systems in the lidocaine
Figure 5. Temperature-composition solid-liquid equilibrium diagram of the lidocaine/L-menthol binary system. The experimental (open circles)
and ideal behavior (dotted line) are shown.
Figure 6. Tammann plots related to the eutectic equilibrium phase
diagram of the lidocaine/L-menthol binary system.
ΔfusH
R · (1T - 1TC) ) -ln[(x)i · (1 - x)j] + ln[(xC)i · (1 - xC)j]
(2)
Figure 7. Plot related to eq 1: ln[x(x-1)] against (1/T - 1/TC).
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molar ratio range of 0.23-0.42.11 Such observations are not
supported by the stable phase diagram. Therefore, a new phase
diagram between lidocaine and L-menthol has to be considered.
3. Lidocaine/L-Menthol Metastable Phase Diagrams.
When cocrystal is not formed, DSC experiments, performed
from mixtures in the molten state, lead to different thermograms
(Figure 8) that can be assigned to eutectic invariants (Figure
9A) with lower temperatures than those encountered for the
stable diagram: 0.3 and 12.3 °C.
The same solid-liquid equilibrium (liquidus curve) is ob-
served for the lidocaine-rich part of the two eutectic diagrams
(Figure 8A). This result indicates a unique transition point
(fusion) for lidocaine. On the contrary, in the L-menthol-rich
part of the diagram, the two distinct liquidi noticed have, as a
consequence, to consider two transition points for L-menthol.
The higher liquidus curve intercepts the temperature axis at the
R L-menthol melting point. By using the same approach, the
lower liquidus curve argues the fusion of the metastable phase
of L-menthol (named the -phase) estimated at 35.7 °C. This
result is in good agreement with previous studies.30 Afterward,
by means of the Schro¨der-van Laar relation (eq 1), the enthalpy
of fusion of the  L-menthol has been estimated to be 71.5 (
1.5 J ·g-1 (11.2 kJ ·mol-1).
The Tammann plots (Figure 9B) related to these metastable
phase diagrams, involving the R- and -phase of L-menthol,
lead to temperatures and compositions of the eutectic points,
respectively, equal to xe,R ) 0.37, Te,R ) 12.3 °C and xe, )
0.35, Te, ) 0.3 °C. Since the straight lines of the Tammann
plots intercept ΔHe ) 0 at x ) 0 and x ) 1 for the two diagrams,
it can be concluded that there is no miscibility in the solid state
between L-menthol and lidocaine. Referring to the diagram
proposed herein, we can suppose that lidocaine may induce a
switch of the L-menthol conformation from the chair (R form)
to a less stable form: the -phase.
It is interesting to point out that, upon heating, metastable
systems may transform to stable ones (Figure 10). Nevertheless,
as may be expected, the closer to 0.5 the lidocaine composition,
the higher the probability of reforming the stable eutectic system.
4. Relative Stability of the Phase Diagrams from a
Thermodynamic Point of View. The thermodynamic analysis
of the three T-x phase diagrams was conducted by determining
the thermodynamic excess quantities in the liquid state for each
eutectic composition at the eutectic temperature. Depression
between experimental and theoretical eutectic temperatures (ΔT
Figure 8. Thermograms of lidocaine/L-menthol mixtures recorded on heating the in situ recrystallized samples (bold solid line) and the recrystallized
samples by annealing (thin solid line). For comparison, the thermograms related to the stable phase diagram are represented by dotted lines. xlidocaine:
(A) 0.11; (B) 0.89. Endothermic transformations give signals pointing up.
Figure 9. (A) Temperature-composition solid-liquid metastable
phase diagram of the lidocaine/L-menthol binary system. The experi-
mental (circles) and ideal behavior (lines) are shown. The data were
collected from the one month annealed samples at -5 °C (open circles,
dotted line) and from the in situ recrystallized samples between -80
and -2 °C (filled circles, solid line). The corresponding Tammann plots
are given in part B.
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) Texp - Tideal) is the result of supplementary intermolecular
interactions in the liquid state (nonideal system). As no solid
solutions had been noticed, no excess enthalpy in the solid state
was considered (ΔHexcesseutectic ) Hexcessliquid - Hexcesssolid ) Hexcessliquid ), and
assuming the additivity of the specific heats in the solid state,31
the excess enthalpy at the eutectic point was determined, for
each phase diagram, using the following expression:
with A and B being the pure compounds, xAeutectic the eutectic
molar ratio of A in the AB mixture, and ΔfusH the enthalpy of
fusion of compound A, B, or the eutectic point.
The corresponding data are collected in Table 4. As expected,
the |Hexcessliquid | values increase with |ΔT|, confirming a lighter
deviation from ideal behavior for the stable diagram. Besides,
a proportional relation between |Hexcessliquid | and |ΔT| can be
underlined. This goes along with the fact that the lower the
melting entropy of the pure substances, the larger the depression
of the freezing point.32
The excess Gibbs energy of the liquid phase (Gexcessliquid ) was
then calculated at the eutectic point, using the EXTXD method.33
Consequently, the excess entropy was estimated from Gexcessliquid )
Hexcessliquid - Te ·Sexcessliquid (Table 4), where Te is the eutectic temperature.
For the stable phase diagram, it is interesting to notice that
the excess entropy at the eutectic points is close to zero, while
for the R and  metastable diagrams, this quantity reaches -8
and -18 J ·mol-1 ·K-1, respectively. These results confirm the
greater relative stability of the phase diagram involving the
addition compound.
Conclusion
Circumspect investigations of thermodynamic phase equilib-
rium are necessary at pharmaceutical scale in order to determine
the ideal condition of preparation, use, and storage of active
principal ingredients in their given state. Such research is also
worthy for topical creams such as lidocaine based mixtures.
Indeed, we ascertained that the previously reported lidocaine/
L-menthol temperature-composition phase diagram was not the
stable one. A new cocrystal between lidocaine and L-menthol
was discovered. The formation of cocrystals can be predicted
using general rules as hydrogen bond rules,34,35 but most of the
time, they are discovered empirically.36 Preparing mixtures using
the new compound was finally the only way to obtain the
lidocaine/L-menthol stable phase diagram which has proved to
be a congruent melting type diagram with two distinguishable
eutectic points on either side of the equimolar composition. As
far as the two metastable phase diagrams are concerned, one is
obtained from lidocaine/L-menthol in the respective stable phase
and the other one from an L-menthol polymorph which may be
induced by the lidocaine/L-menthol interactions. As metastable
systems may transform into stable ones, this paper presents an
overview of phase diagram ambiguities. All of the results
gathered highlight the benefit of determining a stable phase
diagram in order to prevent from its misunderstanding while
collecting data for a metastable diagram. In a pharmaceutical
field where deep eutectics might be promising inasmuch as they
yield to liquid mixtures, our work reveals that these systems
need to be well-defined from a thermodynamic perspective in
order to avoid interpretation of metastable properties. This work
demonstrates that it is vital to conduct physical chemistry studies
before the formulation, patenting, and/or commercialization of
the metastable form of pharmaceutical agents. Conditions such
as temperature, pressure,37 or chemical environment38 could
Figure 10. Thermograms of lidocaine/L-menthol mixtures. xlidocaine: (A) 0.35; (B) 0.86. The dotted line curves correspond to thermograms obtained
with the stable system. Endothermic transformations give signals pointing up.
TABLE 4: Thermodynamic Excess Quantities of the Liquid State for the Lidocaine/L-Menthol Binary Systems Calculated at
the Eutectic Points
experimental data ideal data
diagram type xe Te (°C) xe Te (°C) ΔT (°C) Hexcessliquid (J ·mol-1) Gexcessliquid (J ·mol-1) Sexcessliquid (J ·mol-1 ·K-1)
stable 0.20 28.6 0.20 30.2 -1.6 -400 -430 ∼0
0.61 37.6 0.57 38.7 -1.1 -300 -600 ∼0
metastable R 0.37 12.3 0.37 18.1 -5.8 -2500 -350 -8
metastable  0.35 0.3 0.31 11.3 -11.0 -5300 -310 -18
ΔHexcess
eutectic ) Hexcess
liquid ) ΔfusH
eutectic - (xAeutectic ·ΔfusHA +
(1 - xAeutectic) ·ΔfusHB) (3)
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enhance the formation of the cocrystal which corresponds to
the thermodynamically most stable state of the binary system.39
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